Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Butyrate triglyceride, as a source of butyrate, is being explored for its potential neuroprotective effects in Parkinson's Disease (PD). Butyrate itself is a short-chain fatty acid produced by gut bacteria during fiber fermentation, and it acts as a histone deacetylase (HDAC) inhibitor. Preclinical studies, mainly in animal models, have shown that sodium butyrate can protect dopaminergic neurons and improve motor function by modulating neuroinflammation, oxidative stress, and gene expression associated with neurodegeneration. These mechanisms may be relevant to PD pathology, which involves neuronal loss and chronic inflammation. Some rodent studies have demonstrated that butyrate administration can improve motor deficits and reduce neurodegeneration in toxin-induced models of PD. Additionally, butyrate has been reported to influence the gut-brain axis, which is increasingly recognized as important in PD. However, most published studies use sodium butyrate rather than butyrate triglyceride, and the evidence from human clinical trials is currently lacking. Overall, while there is promising preclinical scientific evidence suggesting a potential benefit of butyrate (and possibly butyrate triglyceride) in PD, the evidence is still early-stage (animal and mechanistic studies), and clinical validation in humans is limited. Hence, butyrate triglyceride use for PD should be considered experimental, with an evidence rating of 2 out of 5.

More about butyrate triglyceride
More about Parkinson's Disease

Other ingredients used for Parkinson's Disease

Other health conditions supported by butyrate triglyceride

Products containing butyrate triglyceride